Meltwater delivers AI-powered innovations in its 2024 Year-End Product Release 29-10-2024, 22:00

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Mereo BioPharma to Participate in Fireside Chat at the SVB 8-02-2023, 19:14